Table 4.

Analysis of risk factors for cardiovascular and cerebrovascular complications in PD patients.

	Roxadustat (n = 60)	rHuEPO (n = 60)
Cardio-cerebrovascular complications, n (%)	6 (10)	16 (26.7)*
Coronary heart diseases, n (%)	1 (1.7)	5 (8.3)
Heart failure, n (%)	3 (5)	6 (10)
Arrhythmia, n (%)	0	1 (2)
Stroke, n (%)	2 (3.3)	4 (6.7)
Changed to HD or combined with HD due to cardio-cerebrovascular complication, n (%)	2 (3.3)	5 (8.3)
All-cause mortality, n (%)	0	1 (1.7)

HD, Hemodialysis; compared with roxadustat group, *p<0.05.